Cordis Corporation, a global leader in innovative technology for
cardiovascular interventions, will introduce the two latest additions to
its portfolio of cardiovascular solutions at EuroPCR 2013, 21-24 May in
Paris. EuroPCR is Europe’s largest meeting for interventional
cardiovascular medicine.
“We are excited to meet with our physician colleagues from around the
world and demonstrate our commitment to them and to their patients,”
said Shlomi Nachman, Worldwide President, Cordis Corporation. In
addition to introducing its newest technology, Cordis will offer
attendees demonstrations, opportunities for hands-on experiences and a
glimpse at advances to come.
Among the highlights Cordis will unveil for meeting attendees are:
-
S.M.A.R.T.® Flex Vascular Stent System*
Designed
to be fully connected and yet flexible, the S.M.A.R.T.® Flex Vascular
Stent System represents the latest innovation in self-expanding
stents. It is engineered to optimize flexibility, fracture resistance
and radial strength with predictable placement. Acquired by Cordis in
March 2013, the S.M.A.R.T.® Flex Vascular Stent System represents an
extension of the Cordis S.M.A.R.T.® Stent platform to address unmet
needs in the treatment of peripheral arterial disease and expand the
company’s therapeutic applications.
EuroPCR attendees can
experience the S.M.A.R.T.® Flex Vascular Stent System in the new
EuroPCR Peripheral Village as well as in the Cordis booth.
-
ADROIT™ Guiding Catheter
Cordis
will launch its latest innovation in guiding catheters: the ADROIT™ 6F
Guiding Catheter**. The ADROITTM Guiding Catheter
incorporates important technological advances. The catheter has been
engineered to accommodate easier advancement of devices with its
0.072’ diameter, the largest inner diameter of any 6F guiding catheter
on the market, while maintaining excellent support and control. These
features offer physicians more options for treating a wide range of
challenging cases, including the treatment of complex lesions and
cases using the radial approach.
The ADROITTM
Guiding Catheter received European CE Mark approval on 17 May.
Attendees
can get a firsthand look at this latest innovation in guiding catheter
technology at the Cordis booth. “ADROIT™: The Innovation and
Technology” sessions will repeat daily, enabling attendees to meet the
experts and see demonstrations.
-
Cordis-Sponsored Symposium on Renal Denervation***
Reflecting
its continual pursuit of innovation to improve treatment options and
patient outcomes, Cordis will sponsor a EuroPCR Symposium: “Advancing
Innovations in Catheter-Based Renal Sympathetic Denervation” on
Wednesday 22 May, 2013, 12.00 pm.
-
Cordis Cardiac & Vascular Institute
Throughout
the Congress, the Cordis Cardiac & Vascular Institute will offer
dedicated educational and hands-on sessions in the Cordis Learning
Centre located in the EuroPCR Training Village. Repeating sessions
include:
Coronary Interventions
-
Radial approach for coronary diagnostic and interventions – hands-on
with the experts
-
Femoral artery access and hemostasis
-
Advanced tips and tricks: vessel preparation and post dilation
Peripheral Interventions
-
Endovascular complication management: renal access
Cordis offers comprehensive training through the Cardiac & Vascular
Institute programme, conducted in co-operation with leading
interventional cardiologists, who have the goal of sharing expertise for
better patient outcomes.
About Cordis Corporation
Cordis Corporation, part of the Johnson & Johnson Family of Companies,
is a worldwide leader in the development and manufacture of
interventional vascular technology. Through the company's innovation,
research and development, Cordis partners with physicians worldwide to
treat millions of patients who suffer from vascular disease. More
information about Cordis Corporation can be found at www.cordis.com
(this site is intended for U.S. visitors).
*The S.M.A.R.T.® Flex Vascular Stent System received European CE
Mark approval for the treatment of vascular disease (iliac, SFA and
popliteal) in January 2009. In the U.S., the S.M.A.R.T.® Flex Biliary
Stent System received 510(k) clearance from the Food and Drug
Administration (FDA) solely for the palliative treatment of biliary
strictures associated with malignant tumors in September 2009;
peripheral vascular indications are investigational in the United States.
** The ADROIT™ Catheter is not approved/cleared for use or
available in the United States.
***This event has been made possible by an educational sponsorship
from Cordis and is intended for Healthcare Professionals only.
(This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995. The
reader is cautioned not to rely on these forward-looking statements.
These statements are based on current expectations of future events. If
underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections of Cordis Corporation and/or Johnson &
Johnson. Risks and uncertainties include, but are not limited to,
general industry conditions and competition; economic factors, such as
interest rate and currency exchange rate fluctuations; technological
advances, new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory
approvals; challenges to patents; changes in behavior and spending
patterns or financial distress of purchasers of health care products and
services; changes to governmental laws and regulations and domestic and
foreign health care reforms; trends toward health care cost containment;
and increased scrutiny of the health care industry by government
agencies. A further list and description of these risks, uncertainties
and other factors can be found in Exhibit 99 of Johnson & Johnson’s
Annual Report on Form 10-K for the fiscal year ended December 30, 2012.
Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov,
www.jnj.com
or on request from Johnson & Johnson. Neither Cordis Corp. nor Johnson &
Johnson undertake to update any forward-looking statements as a result
of new information or future events or developments.)
<div class="copyright">
Copyright Business Wire 2013
</div>